Sun Pharmaceutical Industries Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Sun Pharmaceutical Industries Limited, explained in plain English.

• ▪Sun Pharmaceutical Industries Limited is tracked in the Pharma & Healthcare sector of our NSE large-cap universe.
• ▪Reported fundamentals show a net margin of 20.19%, debt to equity of 5.52.
• ▪Our transparent MaxGrade checklist scores it D (41/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 19.25% with a maximum drawdown of -13.23% and a beta of 0.45 against NIFTY 50.
• ▪Recent coverage: Buy, Sell Or Hold: HDFC Bank, Sun Pharma, Rallis India, Trent | Ask Profit
• ▪Recent coverage: Top 5 Sumeet Bagadia's breakout stocks: Gland Pharma, Astra Micro, Meesho, Westlife, Ujjivan | Target price, stop-loss
• ▪Recent coverage: India's Sun Pharma plans $1 billion local debt sale for loan takeout

Figures from the current session. Market open.